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Abstract
Patients with peripheral artery disease (PAD) are at a high risk 
not only for the classical cardiovascular (CV) outcomes (major 
adverse cardiovascular events; MACE) but also for vascular 
limb events (major adverse limb events; MALE). Therefore, a 
comprehensive approach for these patients should include both 
goals. However, the traditional antithrombotic approach with 
only antiplatelet agents (single or dual antiplatelet therapy) 
does not sufficiently reduce the risk of recurrent thrombotic 
events. Importantly, the underlying cause of atherosclerosis 
in patients with PAD implies both platelet activation and the 
initiation and promotion of coagulation cascade, in which 
Factor Xa plays a key role. Therefore, to reduce residual 
vascular risk, it is necessary to address both targets. In the 
Cardiovascular Outcomes for People Using Anticoagulation 
Strategies (COMPASS) trial that included patients with stable 
atherosclerotic vascular disease, the rivaroxaban plus aspirin 
strategy (versus aspirin) markedly reduced the risk of both CV 
and limb outcomes, and related complications, with a good 
safety profile. In fact, the net clinical benefit outcome composed 
of MACE; MALE, including major amputation, and fatal or critical 
organ bleeding was significantly reduced by 28% with the 
COMPASS strategy, (hazard ratio: 0.72; 95% confidence interval: 
0.59–0.87). Therefore, the rivaroxaban plus aspirin approach 
provides comprehensive protection and should be considered 
for most patients with PAD at high risk of such events.
Keywords: COMPASS, peripheral artery disease, residual risk, 
rivaroxaban.
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Introduction
Peripheral artery disease (PAD) is very common in clinical 
practice, although underdiagnosed.1,2 It has been estimated 
that more than 200 million people worldwide are affected 
by lower extremity PAD.3 The prevalence of PAD markedly 
increases with age, from approximately 5% in patients 
aged 45–49 years to around 10% in patients aged 65–74 
years and nearly 20% by the age of 80 years.3,4 In Spain, in a 
cross-sectional analysis of 1568 subjects, aged 45–74 years, 
the prevalence of PAD was 3.8%.5 In the MERITO study, the 
prevalence of PAD evaluated by the ankle–brachial index in 
patients with metabolic syndrome was 28% and in patients 
with a previous coronary event, cerebrovascular disease, or 
both, it was 34, 32, and 54%, respectively.6,7
In addition, it is expected that these numbers will increase in 
the following years due to the aging of the population and 
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the increased rates of diabetes, hypertension, and smoking.3 
Importantly, the majority of patients with PAD do not refer 
specific symptoms. Thus, according to different studies, up to 
one-third of patients with an ankle–brachial index <0.90 have 
typical intermittent claudication.4,8,9 
Atherosclerotic disease is the underlying cause of PAD.1,2 As 
atherosclerosis is often generalized, patients with PAD have 
usually more vascular beds affected. Thus, in the Reduction of 
Atherothrombosis for Continued Health (REACH) registry, 61.5% 
of patients with PAD had concomitant disease in other vascular 
beds (versus 24.7% of patients with coronary artery disease 
[CAD]).10 Patients with polyvascular disease have an increased 
risk of morbidity and mortality, being greater as a higher 
number of vascular beds are affected.11–14
Patients with symptomatic or asymptomatic PAD have 
an increased risk of cardiovascular (CV) death, myocardial 
infarction, and stroke (major adverse cardiovascular events; 
MACE).15 Compared with patients without PAD, the risk of CV 
death is increased among patients with asymptomatic and 
symptomatic PAD, by 5 and 11%, respectively.16 In addition, 
approximately one-fifth of patients with symptomatic PAD 
have myocardial infarction, and around 10–15% die after a 
5-year period of follow-up.17 Of the one hand, the risk of CV 
death, myocardial infarction, or stroke is even higher in patients 
with PAD than in patients with CAD.12 On the other hand, in 
patients with asymptomatic carotid stenosis, approximately 
two-thirds of late deaths are related to cardiac events, with an 
annual mortality rate of 2.9%.18
Patients with PAD are not only at high risk of MACE, but also 
of major adverse limb events (MALE), including severe limb 
ischemia and amputation.19 Thus, it has been calculated that 
the annual incidence of major amputation ranges between 120 
and 500 per million, and in Western Europe, the PAD-related 
mortality reached 3.5 per 100,000 individuals (excluding 
stroke and myocardial infarction) in 2010, and the years of 
life lost due to PAD were estimated at 31.7 years per 100,000 
inhabitants.1,20,21 Therefore, in patients with PAD, it is not only 
mandatory to reduce MACE, but also MALE. 
In a specific substudy of the Cardiovascular Outcomes for 
People Using Anticoagulation Strategies (COMPASS) trial, which 
analyzed the impact of MALE on the prognosis of patients with 
lower extremity PAD, showed that after MALE,  
the 1-year cumulative risk of subsequent hospitalization, 
vascular amputations, death, and MACE were 61.5; 20.5; 8.3; 
and 3.7%, respectively. Importantly, experiencing MALE 
dramatically increased the risk of subsequent amputations 
(hazard ratio [HR]: 197.5; p<0.0001), and death (HR: 3.23; 
p<0.001) (Figure 1).22 




























MACE + total vascular
amputation
All-cause mortality
Before MALE After MALE
HR 1.52; 95% CI 0.72–3.24;
P=0.27
HR 197.5; 95% CI 97.33–400.8;
P <0.0001
HR 7.56; 95% CI 5.14–11.12;
P <0.0001
HR 3.23; 95% CI 1.87–5.56;
P <0.0001
MACE: cardiovascular death, myocardial infarction, stroke.
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As a result, PAD is a very common condition in routine 
practice, with very high rates of MACE and MALE. Reducing 
both and the related complications with the appropriate 
prophylaxis is mandatory. In this narrative review, data about 
how to reduce residual risk through the best antithrombotic 
approach among patients with PAD, with a particular focus 
on the COMPASS trial, are updated in order to provide some 
practical recommendations about its use in this population. For 
this purpose, a search was performed (up to March 2020) on 
PubMed (MEDLINE), using the MeSH terms [peripheral artery 
disease] + [COMPASS] + [rivaroxaban] + [treatment]. Original 
data from clinical trials, prospective and retrospective studies, 
and more useful reviews were selected. 
Antithrombotic treatment in 
patients with PAD
Progressive atherosclerosis is the underlying cause of PAD and 
results in a spectrum of symptoms that, in the case of lower 
extremity PAD, ranges from asymptomatic to intermittent 
claudication, ischemic rest pain, and major and minor trophic 
changes. On the other hand, acute limb ischemia (ALI) is caused 
by native atherosclerotic plaque disruption and thrombus 
formation, and in the case of patients previously revascularized, 
thrombosis of the stent or graft.1,2,20,23 After atherosclerotic 
plaque disruption, the thrombogenic subendothelial matrix 
is exposed to circulating blood, leading to activation of 
circulating platelets and the coagulation cascade and lastly to 
thrombus formation.24–28 As a result, to reduce CV outcomes 
and the risk of PAD-related complications, it is necessary not 
only to control CV risk factors, but also follow a comprehensive 
antithrombotic approach that includes not only acting on 
platelets but also on coagulation inhibition.29 
With regard to antithrombotic therapy, in patients with lower 
extremity PAD, the European guidelines recommend the use of 
long-term single antiplatelet therapy in symptomatic patients 
(recommendation I A) and in all patients who have undergone 
revascularization (recommendation I C). Furthermore, 
clopidogrel may be preferred over aspirin (recommendation 
IIb B). In addition, dual antiplatelet therapy with aspirin and 
clopidogrel for at least 1 month should be considered after 
infra-inguinal stent implantation (recommendation IIa C) and 
may be considered in below-the-knee bypass with a prosthetic 
graft (recommendation IIb B). Importantly, antiplatelet therapy 
is not routinely indicated in patients with asymptomatic PAD 
(recommendation III A).1 On the other hand, long-term single 
antiplatelet therapy is also recommended in patients with 
symptomatic carotid stenosis (recommendation I A), and dual 
antiplatelet therapy with aspirin and clopidogrel for at least  
1 month after carotid artery stenting (recommendation I B).1
Despite these indications, patients with PAD treated with 
current evidence-based recommended care have an 
unacceptably high residual CV risk.29,30 This is not surprising as 
the current only antiplatelet-based antithrombotic approach is 
insufficient to effectively reduce not only MACE but also MALE 
in PAD patients.31,32 In addition, the 2017 European guidelines 
recognize that the results of the COMPASS trial were not 
included at the time of publication but should be updated after 
a critical analysis.1
Thus, the evidence supporting the use of aspirin or clopidogrel 
to prevent MACE in PAD patients remains insufficient. In a 
meta-analysis of 18 clinical trials involving 5269 individuals 
with PAD, treatment with aspirin alone resulted in a statistically 
nonsignificant reduction in MACE, and only a significant 
decrease in nonfatal stroke (Table 1).33 In another meta-
analysis of 287 studies, aspirin reduced the risk of MACE among 
patients with atherosclerotic vascular disease, including those 
with PAD.34 In patients with symptomatic PAD and no history 
of stroke/transient ischemic attack included in the REACH 
registry, despite 61% of patients treated with aspirin and 83% 
with at least one antiplatelet agent, MACE rates reached 4.7% 
during the first year and increased continuously by 4–5% per 
year; the limb ischemic event rate was 5.7% at 2 years.35 In the 
Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events 
(CAPRIE) trial, among 19,185 patients with atherosclerotic 
vascular disease, including recent ischemic stroke, recent 
myocardial infarction, or symptomatic PAD, after a mean 
follow-up of 1.91 years, compared with aspirin, clopidogrel 
significantly reduced the risk of MACE, including the subgroup 
of patients with PAD (Table 1).36 In the Clopidogrel for High 
Atherothrombotic Risk and Ischemic Stabilization, Management 
and Avoidance (CHARISMA) study, in the subgroup of 
patients with prior myocardial infarction, ischemic stroke, or 
symptomatic PAD, while the combination of clopidogrel plus 
aspirin (versus aspirin alone) significantly reduced the risk of 
MACE by 17%, there was a nonsignificant reduction of 13% 
in the PAD subpopulation. No reduction of mortality was 
observed. Moderate bleeding, but not severe bleeding, was 
more common with the combination (Table 1).37
This limited efficacy of antiplatelet agents in patients with PAD 
has not only been limited to the traditional antiplatelet agents, 
such as aspirin or clopidogrel, but also with the newer ones. 
The Trial to Assess the Effects of Vorapaxar in Preventing Heart 
Attack and Stroke in Patients with Atherosclerosis–Thrombolysis 
in Myocardial Infarction 50 (TRA 2P–TIMI 50) study compared 
vorapaxar plus aspirin versus aspirin in patients with chronic 
atherosclerotic vascular disease. In the subgroup of 3787 
patients with chronic symptomatic PAD, vorapaxar did not 
reduce the risk of MACE, but significantly reduced the rates of 
hospitalization for ALI and peripheral artery revascularization 
by 42 and 16%, respectively. Major bleeding was more common 
with the combination (Table 1).38 Ticagrelor, 90 mg, twice daily 
was compared with clopidogrel, 75 mg, once daily in 13,885 
patients with symptomatic PAD in the Effects of Ticagrelor and 
Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) 
trial. After a median follow-up of 30 months, rates of MACE, 
ALI, CV death, and major bleeding were similar between both 
groups (Table 1).39 In the Prevention of Cardiovascular Events in 
Patients with Prior Heart Attack Using Ticagrelor Compared to 
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CI: 0.66–0.86; p<0.001). This beneficial effect was independent 
of the presence of PAD (p for interaction was 0.61). The risk of 
ischemic stroke, myocardial infarction, ALI, or death from CAD 
was also reduced by 28% with the combination (HR: 0.72; 95% 
CI: 0.63–0.83; p<0.001), and also the risk of MACE or ALI by 26% 
(HR: 0.74; 95% CI: 0.65–0.85; p<0.001). The risk of stroke and 
hospitalization for CV causes was also significantly reduced by 
the rivaroxaban plus aspirin approach. But more importantly, 
there was a trend toward a lower risk of both CV death and 
death from any cause with the combination of rivaroxaban 
plus aspirin compared with aspirin. Although the risk of major 
bleeding was increased with the combination (HR: 1.70; 95% 
CI: 1.40–2.05; p<0.001), the risk of fatal bleeding or intracranial 
bleeding did not significantly differ between the groups.54 
Importantly, while there was an absolute risk reduction of 0.5% 
in CV death between aspirin alone and the rivaroxaban plus 
aspirin approach (from 2.2 to 1.7%; p=0.02) and an absolute risk 
reduction of 0.7% in death from any cause (from 4.1 to 3.4%; 
p=0.01), there was a nonsignificant absolute increase of 0.1% in 
fatal bleeding (from 0.1 to 0.2%; p=0.32), without any difference 
in the risk of nonfatal symptomatic intracranial hemorrhage 
(0.2% in both groups; p=0.77).54 In summary, in patients with 
chronic atherosclerotic vascular disease, the beneficial effect of 
the combination of rivaroxaban plus aspirin on MACE is much 
higher than the possible increase in bleeding risk.
Efficacy and safety of the vascular 
dose of rivaroxaban in patients 
with established PAD
The COMPASS substudy included a total of 7470 patients with 
PAD. The definitions of PAD, according to the COMPASS criteria, 
are summarized in Table 2. Briefly, to be included, patients 
should have a history of PAD of the lower extremities (previous 
revascularization, amputation, or intermittent claudication), of 
the carotid arteries (previous revascularization or asymptomatic 
≥50% carotid artery stenosis), or patients with ischemic heart 
disease and an ankle–brachial index <0.90. Although all these 
patients were included according to PAD criteria, there were 
relevant differences in the clinical profile of these subgroups 
of patients. With regard to the exclusion criteria, patients who 
required dual antiplatelet therapy for any clinical condition 
or with a high risk of bleeding were excluded from the study 
(Table 2).41,53
Mean age of patients with PAD was 68 years, 81% had 
symptomatic PAD, 55% symptomatic PAD of lower extremities, 
26% previous carotid revascularization or ≥50% carotid stenosis, 
20% CAD and an ankle–brachial index <0.90, and 4.5% prior 
limb or foot amputation. In addition, 66% of patients with PAD 
had concomitant CAD and 28% renal insufficiency (Table 3).41
Among PAD patients, compared with aspirin, the rivaroxaban 
plus aspirin approach significantly reduced the risk of MACE 
by 28%; the risk of ischemic heart disease death, myocardial 
Placebo on a Background of Aspirin–Thrombolysis in Myocardial 
Infarction 54 (PEGASUS–TIMI 54) trial, 21,162 patients with prior 
myocardial infarction (1–3 years) were randomized to receive 
ticagrelor, 90 mg, twice daily plus aspirin and ticagrelor, 60 
mg, twice daily plus aspirin or placebo plus aspirin. Compared 
with aspirin in monotherapy, the combination of ticagrelor, 90 
mg, and aspirin did not significantly reduce the risk of MACE, 
ischemic stroke, or CV death, but significantly reduced the risk 
of MALE by 51%. By contrast, ticagrelor, 60 mg, plus aspirin 
significantly reduced the risk of MACE and CV deaths by 31 and 
53%, respectively, but not the risk of MALE or ischemic stroke 
(Table 1).40 All these data clearly indicate that treating PAD 
patients with antiplatelets (single or dual antiplatelet therapy) 
does not provide a comprehensive approach with the double 
target of reducing MACE and MALE.41
On the other hand, full anticoagulation with vitamin K 
antagonists has not been shown to provide further protection 
compared with single antiplatelet therapy in patients with 
PAD.42,43
Finding an antithrombotic regimen that targets both platelet 
and anticoagulation cascade activation may be more effective 
in preventing MACE and MALE in patients with PAD.25,26,44–47 
In addition, experimental data have shown that the inhibition 
of Factor Xa decreases inflammation and platelet-dependent 
thrombin generation; attenuates neointima formation after 
vascular injury; has protective, repairing, and fibrinolytic effects 
on vascular endothelium; and stabilizes atherosclerotic plaque 
and reduces its progression. Of note, most of these positive 
data on experimental models have been obtained specifically 
with rivaroxaban.48–52 All these data strongly suggest that an 
inhibition of Factor Xa, as rivaroxaban, could exert a positive 
impact on patients with PAD. This hypothesis has been tested 
in the COMPASS study.
The COMPASS study was a double-blind superiority trial that 
included a total of 27,395 subjects with chronic atherosclerotic 
vascular disease (CAD or PAD). Patients were randomly allocated 
to receive rivaroxaban, 2.5 mg, twice daily combined with 
aspirin, 100 mg, once daily, rivaroxaban, 5 mg, twice daily or 
aspirin, 100 mg, once daily. At baseline, mean age was 68 years, 
91% of patients had CAD (62% previous myocardial infarction; 
73% only CAD; 18% CAD and PAD), and 27% had PAD (9% only 
PAD). The study was prematurely stopped due to the beneficial 
effects found with rivaroxaban, 2.5 mg, twice daily (vascular 
dose of rivaroxaban) plus aspirin over aspirin after a mean 
follow-up of only 23 months.53,54 This is very relevant as the 
Kaplan–Meier survival curves between rivaroxaban plus aspirin 
and aspirin alone separated over time, mainly after the first 
year of treatment, but the excess of bleeding risk dramatically 
fell after 1 year of therapy.53,54 As a result, compared with the 
traditional approach of aspirin alone in patients with chronic 
atherosclerotic vascular disease, the net clinical benefit of the 
rivaroxaban plus aspirin approach increases over time.
Overall, compared with aspirin, the rivaroxaban plus aspirin 
combination reduced the risk of MACE by 24% (HR: 0.76; 95% 
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Table 2. Definition of peripheral artery disease and main exclusion criteria in the COMPASS trial.41,53
•	 Definition of PAD (any of the following):
  Previous aortofemoral or limb bypass surgery, or 
percutaneous transluminal angioplasty revascularization 
of the iliac/infrainguinal arteries, or
  Previous limb/foot amputation due to arterial vascular 
disease, or
  History of intermittent claudication and ≥1 of the 
following:
•	 an ankle/arm blood pressure ratio <0.90
•	 significant peripheral artery stenosis (≥50%) (detected 
by angiography or duplex ultrasound)
•	 previous carotid revascularization or asymptomatic 
carotid artery stenosis ≥50% (detected by duplex 
ultrasound or angiography).
•	 Main exclusion criteria:
  high risk of bleeding
   stroke ≤30 days or any history of hemorrhagic or 
lacunar stroke
  severe heart failure (LVEF< 30% or NYHA class III or IV)
  eGFR < 15 mL/min
 need for dual antiplatelet therapy, or anticoagulation.
eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PAD, 
peripheral artery disease.
Table 3. Baseline clinical characteristics of patients with peripheral artery disease (lower 
extremities or carotid) included in the COMPASS trial.41
Total population
Patients with PAD (n)
Symptomatic PAD of the lower extremities (n)
Previous carotid revascularization or carotid stenosis ≥50% (n)












    Current
    Former






Renal insufficiency (%) 28
Previous stroke (%) 7
Concomitant medications
Antiplatelets (%) 87
Lipid-lowering drugs (%) 83
Renin–angiotensin system inhibitors (%) 70
ABI, ankle–brachial index; CAD, coronary artery disease; PAD, peripheral artery disease.
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Major bleeding occurred more frequently with the combined 
therapy than with aspirin alone (3 versus 2%; HR: 1.61; 95%  
CI: 1.12–2.31; p=0.0089), mainly gastrointestinal. Importantly, 
fatal bleeding and non-fatal symptomatic intracranial 
hemorrhage occurred in less than 1% of patients, regardless of 
the assigned group (Figure 2).41 
As a result, while the proportion of patients with MACE plus 
MALE decreased from 9 to 6% and the risk of death from 6 
to 5% with the combined therapy, the risk of fatal bleeding 
was <1% in both groups (Figure 2). In addition, the net clinical 
benefit outcome composed of MACE, MALE, including major 
amputation, and fatal or critical organ bleeding was reduced 
by 28% with the rivaroxaban plus aspirin strategy compared to 
aspirin alone (HR: 0.72; 95% CI: 0.59–0.87; p=0.0008). As a result, 
during a 21-month period, for every 1000 patients treated with 
the COMPASS strategy, 27 events of MACE or MALE, including 
major amputation, would be prevented, but 1 fatal and 1 
critical organ hemorrhage would occur.41 
infarction, ischemic stroke, and ALI by 32%; the risk of CV death, 
myocardial infarction, ischemic stroke, and ALI by 29%; and the 
risk of MACE plus MALE by 31% (HR: 0.69; 95% CI: 0.56–0.85; 
p=0.0004). In addition, the risk of stroke was significantly 
reduced by the combination of rivaroxaban plus aspirin (HR: 
0.54; 95% CI: 0.33–0.87), and there was a trend toward a lower 
risk of CV death (HR: 0.82; 95% CI: 0.59–1.14) and death for any 
cause (HR: 0.91; 95% CI: 0.72–1.16) (Figure 2).41 Of note, the 
effects of low-dose rivaroxaban plus aspirin versus aspirin alone 
on the combined outcome of MACE and MALE including major 
amputation were consistent regardless the presence of CAD (p 
for interaction was 0.33).41
Compared with the traditional approach of aspirin alone, the 
combination of rivaroxaban plus aspirin markedly reduced the 
prespecified limb outcomes. Thus, the rivaroxaban plus aspirin 
approach significantly reduced the risk of ALI by 44%, the risk of 
MALE by 46%, the risk of all vascular amputations by 60%, and 
the risk of major amputations by 70% (Figure 3).41
Figure 2. Effects of treatment on MACE, MACE or MALE including major amputation, MACE plus acute limb 
ischemia, death and fatal bleeding in patients with chronic peripheral artery disease from the 
COMPASS study.41
Low-dose rivaroxaban + aspirin Aspirin alone
HR 0.72; 95% CI 0.57–0.90;
P=0.0047
HR 0.69; 95% CI 0.56–0.85;
P=0.0004
HR 0.91; 95% CI 0.72–1,16
HR 0.71; 95% CI 0.57–0.88;
P=0.0019











MACE MACE1 + ALI Death Fatal bleeding Net clinical benetMACE or MALE
including major
amputation 
MACE: Cardiovascular death, myocardial infarction, MACE1: Cardiovascular death, myocardial infarction, ischemic stroke;
MALE: major adverse limb event; ALI: acute limb ischemia.
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Approximately one-third of patients with symptomatic PAD 
have heart failure (HF).59 In fact, the risk of HF is doubled in 
patients with PAD60 or even more in elderly patients.61 In 
the COMPASS trial, although patients with severe HF were 
excluded from the study, 22% of patients had a history of 
mild-to-moderate HF. In the COMPASS trial, in patients with 
chronic ischemic heart disease or PAD and a history of mild 
or moderate HF, the rivaroxaban plus aspirin approach (versus 
aspirin) resulted in a similar relative but higher absolute risk 
reduction in MACE and mortality compared to those patients 
without HF, with a similar excess hazard for major bleeding, 
independently of the presence of HF.62
Discussion
Patients with PAD are at a very high risk of both MACE and 
MALE, and treatment should be necessarily focused on both 
targets.19,63,64 Thus, although CV death is the main cause of 
mortality in this population,15–17 it should not be forgotten that 
in patients with PAD who experience MALE, the risk of death 
increases by 3 and the risk of subsequent vascular amputation 
by 200.22 The traditional approach with antiplatelet treatment 
with a single or dual antiplatelet therapy has failed in providing 
complete protection of patients with PAD. For example, in the 
Beneficial effects of the vascular 
dose of rivaroxaban in patients 
with established PAD and other 
clinical conditions
Many patients with PAD have other vascular beds affected, 
thus increasing the risk of CV morbidity and mortality.10–14 
In the COMPASS trial, two-thirds of patients with PAD had 
concomitant CAD,41 and among patients with CAD, 20% of 
patients had also PAD, defined according to COMPASS inclusion 
criteria.55 In those patients with ischemic heart disease, the 
presence of PAD did not modify the effects of the rivaroxaban 
plus aspirin approach on the primary outcome (p for interaction 
was 0.37), major bleeding (p for interaction was 0.46), and net 
clinical benefit (p for interaction 0.24).55
Chronic kidney disease increases both the risk of bleeding and 
MACE.56,57 In the COMPASS study, rates of MACE and major 
bleeding were more common in those patients with renal 
insufficiency than in those individuals with normal function. 
Importantly, while the beneficial effect of the rivaroxaban plus 
aspirin approach over aspirin on MACE was independent of 
renal function, there was no excess hazard of major bleeding.58
Figure 3. Effects of treatment on prespecified limb outcomes in patients with chronic 
peripheral artery disease from the COMPASS study.41






HR 0.56; 95% CI 0.32–0.99;
P=0.042
HR 0.67; 95% CI 0.35–1.26;
P=0.21
HR 0.54; 95% CI 0.35–0.84;
P=0.0054
HR 0.40; 95% CI 0.20–0.79;
P=0.0069
HR 0.30; 95% CI 0.11–0.80;
P=0.0011
ALI: acute limb ischemia; MALE: Major adverse limb event
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intracranial bleeding (<1%), the reduction in the risk of these 
outcomes by the combination of rivaroxaban plus aspirin was 
greater than the possible risk of fatal or intracranial bleeding. 
In addition, most of the major bleedings had a gastrointestinal 
origin and rarely are fatal or leave permanent sequelae.41 In 
addition, compared with aspirin alone, the risk of major bleeding 
was increased with the rivaroxaban plus aspirin approach only 
during the first year of treatment, but not during the following 
years.55 Therefore, the concern about the risk of bleeding should 
not be to avoid the use of the combination of the vascular dose 
of rivaroxaban plus aspirin in patients with PAD at high risk 
of MACE or MALE. However, it should be emphasized that as 
these data are provided from post-hoc subgroup analysis, the 
generalization of the results may be limited. 
Rivaroxaban, 2.5 mg, twice daily, coadministered with 
75–100 mg aspirin, once daily is currently indicated for the 
prevention of atherothrombotic events in adult patients with 
CAD or symptomatic PAD at high risk of ischemic events.71 
However, it is important to ascertain which patients with 
chronic atherosclerotic vascular may benefit more from the 
COMPASS strategy.24,31,44,64,72,73 In patients with PAD, not only 
those patients at high risk of MACE but also at high risk of 
MALE should be taken into account.22,74–76 A recent analysis 
of the COMPASS trial showed that patients with ≥2 vascular 
beds affected, HF, renal insufficiency, diabetes, or having a 
high REACH score had the highest risk of recurrent vascular 
events.74 Other recent analysis of the COMPASS trial showed 
that those patients with PAD and Fontaine classification III 
or IV ischemia, history of peripheral revascularization, prior 
amputation, or patients with MALE, treated with aspirin 
alone as antithrombotic therapy, had the highest risk of 
recurrent limb events.22 Considering these studies and other 
recommendations, excepting for those patients with any of 
the main exclusion criteria of the COMPASS trial (high risk 
of bleeding, recent stroke, severe HF or renal insufficiency, 
and need for dual antiplatelet therapy or anticoagulation), 
those patients with PAD who meet any of the criteria for high 
risk of MACE or MALE may be considered for the treatment 
with the rivaroxaban plus aspirin approach (Table 4). On the 
other hand, the Vascular Outcomes studY of ASA along with 
rivaroxaban in Endovascular or surgical limb Revascularization 
for PAD (VOYAGER PAD) study has shown in patients with PAD 
who have undergone lower-extremity revascularization that 
rivaroxaban, 2.5 mg, twice daily plus aspirin was associated 
with a significantly lower incidence of the composite outcome 
of ALI, major amputation for vascular causes, or MACE 
compared with aspirin alone. In addition, the incidence of 
TIMI major bleeding was similar between both groups, but 
the incidence of International Society on Thrombosis and 
Haemostasis (ISTH) major bleeding was significantly higher 
with the combination.77
A number of studies have analyzed whether the combination 
of the vascular dose of rivaroxaban plus aspirin is a cost-
effective approach according to different National Healthcare 
Systems. All of them have shown that in those patients with 
PEGASUS–TIMI 54 study, while ticagrelor, 60 mg, reduced the risk 
of MACE, no beneficial effect was obtained on limb outcomes.40 
In the CHARISMA trial, the combination of clopidogrel plus 
aspirin did not reduce the risk of MACE compared with 
aspirin in monotherapy.36 Full anticoagulation with vitamin K 
antagonists has not been shown to provide further protection 
over antiplatelet therapy in PAD patients.42,43 By contrast, 
the COMPASS trial demonstrated in the PAD population that 
compared with aspirin, 100 mg, once daily in monotherapy, 
the rivaroxaban, 2.5 mg, twice daily plus aspirin, 100 mg, once 
daily approach significantly reduced the risk of MACE by 28% 
and the risk of MALE by 46%. Even more, the combination of 
vascular doses of rivaroxaban (2.5 mg twice daily) plus aspirin 
reduced by 60% the risk of all vascular amputations and by 70% 
the risk of major amputations (Table 1).41 The development of 
atherosclerosis in patients with PAD includes both platelet and 
coagulation cascade activation, with Factor Xa playing a key 
role. The good results of the COMPASS trial are in line with the 
underlying cause of atherosclerosis.24–28,48–52 Importantly, a 
great proportion of patients with PAD in clinical practice meet 
the inclusion criteria of the COMPASS trial, indicating that the 
results of this study can be extended to this population.65–67  
As a result, all these data strongly suggest that the rivaroxaban 
plus aspirin approach should be considered as the first choice for 
the treatment of patients with PAD to achieve the double target 
of MACE and MALE. In fact, current guidelines recommend the 
use of the combination of aspirin plus rivaroxaban, 2.5 mg, twice 
daily in different clinical settings. Thus, the 2019 ESC Guidelines 
of chronic coronary syndromes recommend the use of the 
rivaroxaban plus aspirin approach in those patients at high or 
moderate risk of ischemic events, but without a high bleeding 
risk (recommendation IIb).68 However, despite the COMPASS 
trial showing a trend toward a reduction of mortality rates in 
this population, but not other antithrombotic approaches (i.e. 
clopidogrel, ticagrelor, or prasugrel), these guidelines performed 
the same recommendation for all these drugs. Nonetheless, 
in the light of the results of clinical trials, net clinical benefit 
clearly favors rivaroxaban over other antithrombotic strategies, 
and the recommendations of use should not have been the 
same. On the other hand, the 2019 ESC Guidelines on diabetes, 
prediabetes, and CV diseases indicate that the low-dose 
rivaroxaban, 2.5 mg, twice daily plus aspirin, 100 mg, daily 
may be considered in patients with diabetes and symptomatic 
lower extremity artery disease (recommendation IIa).69 The 
global vascular guidelines on the management of chronic 
limb-threatening ischemia state that low-dose aspirin and 
rivaroxaban, 2.5 mg, twice daily should be considered to reduce 
adverse CV events and lower extremity ischemic events in 
patients with chronic limb-threatening ischemia (grade 2; level 
of evidence B).70
The COMPASS trial showed that the rivaroxaban plus aspirin 
approach had a higher risk of major bleeding than aspirin alone. 
However, there was no excess in fatal or intracranial bleeds. 
Of note, as the risk of MACE or MALE (7 and 2%, in the aspirin 
group, respectively) was much higher than the risk of fatal or 
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Table 4. Patients with peripheral artery disease who may benefit more from a COMPASS strategy.22,31,74–76
To reduce MACE To reduce MALE
•	 ≥2 vascular beds
•	 Previous stroke/transient ischemic attack




•	 High REACH score
•	 Fontaine classification III or IV ischemia
•	 History of peripheral revascularization  
(surgery or angioplasty)
•	 Previous ischemic limb events
•	 Previous amputation or high risk of amputation
•	 Patients with MALE, treated with aspirin alone as 
antithrombotic therapy
MACE, major adverse cardiovascular events (cardiovascular death, stroke, myocardial infarction); MALE, major adverse 
limb events: acute or chronic limb ischemia, including all major vascular amputations.
lower extremity PAD or carotid artery disease, rivaroxaban plus 
aspirin therapy is effective and cost effective in the prevention 
of recurrent CV disease compared to the traditional approach 
of aspirin therapy alone.78–80 These data emphasize its use in 
clinical practice for the majority of patients with PAD at high 
risk of vascular or limb events.
In light of all these data, more efforts are required to implement 
the COMPASS strategy in patients with PAD in routine practice. 
Thus, guidelines should be updated including the information 
of the COMPASS trial and its substudies, indicating those 
patients who may benefit more from this approach. In addition, 
specific educational activities for general practitioners, vascular 
specialists, cardiologists, and internists would be very helpful 
to better understand the benefits and risks of the rivaroxaban 
plus aspirin approach for PAD patients. Importantly, screening 
of PAD should be emphasized not only by general practitioners 
but also by other specialists who manage patients with vascular 
disease, regardless of the vascular bed affected. Moreover, 
more cost-effective studies are mandatory in order to facilitate 
a potential reimbursement by the authorities.
Conclusions
Patients with PAD have a high risk of both adverse vascular 
and limb outcomes. The underlying cause of atherosclerosis 
in PAD patients implies not only platelet activation but also 
the initiation and promotion of coagulation cascade, in which 
Factor Xa plays a key role. The traditional antithrombotic 
approach with only antiplatelet agents (single or dual 
antiplatelet therapy) has failed to provide complete protection 
in PAD patients. By contrast, the rivaroxaban plus aspirin 
strategy markedly reduces the risk of both MACE and MALE, 
and related complications, with a low risk of bleeding. 
Therefore, the rivaroxaban plus aspirin approach provides a 
comprehensive protection and should be considered for many 
patients with PAD at high risk of such events.
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